Cell Proliferation News and Research

RSS

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

7 Dec 2009

BUSM researchers report an inverse association between dairy intake and fibroid risk

Boston University School of Medicine (BUSM) researchers at the Slone Epidemiology Center found that black women with high intake of dairy products have a reduced incidence of uterine leiomyomata (fibroids). This report, based on the Black Women's Health Study, appears in the current issue of the American Journal of Epidemiology.

4 Dec 2009

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto Biopharma Inc., is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

4 Dec 2009

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

TGF--1 suppresses the growth of cancer cells, find researchers

UT Southwestern Medical Center researchers have found that a naturally occurring protein -- transforming growth factor beta1 (TGF--1) -- which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.

2 Dec 2009

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Cell migration is an important process in the development of organisms, as well as during immune surveillance and wound healing. For cancer development, the potential of cells to migrate or to grow invasively is, in addition to proliferation, the most important disease-causing factor. The inhibition of cell migration is a key target of the new anti-inflammatory therapies.

25 Nov 2009

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition.

25 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.

23 Nov 2009

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Universitat Autònoma de Barcelona (UAB) researchers have confirmed that a diet rich in polyphenols and polyunsaturated fatty acids, patented as an LMN diet, helps boost the production of the brain's stem cells -neurogenesis- and strengthens their differentiation in different types of neuron cells.

23 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.

19 Nov 2009

Cell Proliferation News and Research

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

BUSM researchers report an inverse association between dairy intake and fibroid risk

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

New approach to identify molecules that prevent immune cells from attacking body

DiaMedica to acquire all issued and outstanding shares of Sanomune

TGF--1 suppresses the growth of cancer cells, find researchers

Glutamatergic nerve cells regularly generated in the brain

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Mutated IDH1 gene linked to the progression of gliomas

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

New biomarkers can predict patients' response to certain drugs

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News